Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumor Effect of Humalutin® in Three Lymphoma Models at AACR 2018

OSLO, Norway, March 15 2018 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin's lymphoma (NHL) at the American Association for Cancer Research (AACR) Annual Meeting 2018. The meeting takes place from 14-18 April in Chicago, USA.

The preclinical data to be presented, described in an abstract published yesterday (link), demonstrate that:

In tumour cell lines:

  • The unlabelled anti-CD37 antibody (NNV003) kills tumour cells mainly through an immunological process called antibody dependent cellular cytotoxicity
  • Humalutin® (177Lu-NNV003) was found to inhibit tumour cell growth.

In preclinical lymphoma models:

  • Humalutin® has shown significant tumour uptake and demonstrated an anti-tumour effect in all three NHL models (mantle cell lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia).

Jostein Dahle, Chief Scientific Officer commented: "The data is important for Nordic Nanovector as they provide an early demonstration of the potential that Humalutin® has for treating different types of NHL. These encouraging data provide further support to the planned clinical development of Humalutin®, for which Nordic Nanovector expects to launch a Phase I study in NHL in the second half of 2018."

Details for the poster presentation are as follows:

Poster Title: In vitro and in vivo evaluation of the beta-emitting lutetium-177 labeled anti-CD37 antibody radionuclide conjugate 177Lu-NNV003 in DLBCL, CLL and MCL models Session Date and Time: Sunday 15 April 2018, 1:00 PM - 5:00 PM (Central Time) Location: McCormick Place South, Exhibit Hall A, Poster Section 39, Poster Board Number: 11 Session Category: Experimental and Molecular Therapeutics Session Title: Modulators of Ionizing Radiation and Other Radiotherapeutics Permanent Abstract Number: 848

The poster will be available on 15 April 2018 on the company's website at:

For further information, please contact:

IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762

Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44-207-638-9571


Back to news